2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.101 Paul Lozowicki Abstract

PP01.101 Paul Lozowicki Abstract

Pdf Summary

This study aims to estimate the costs of adverse events (AE), surgery, and medical resource use (MRU) in the first year of treatment for patients with resectable non-small cell lung cancer (rNSCLC) receiving neoadjuvant nivolumab plus platinum doublet chemotherapy (NPDC) compared to those receiving neoadjuvant platinum doublet chemotherapy (neoPDC). Data from the CheckMate-816 trial were used to determine the frequency of AE, surgery type and approach, and treatment patterns. Unit costs from US published databases were then combined with this data to estimate the costs per patient. The estimated costs for NPDC were found to be 5.7% lower compared to neoPDC. This difference was primarily driven by lower costs associated with neoadjuvant AE, adjuvant AE, and surgical complications. Patients receiving NPDC incurred fewer adjuvant AE costs due to reduced use of adjuvant therapy and a less costly mix of adjuvant AE. The estimated cost of surgery per patient receiving NPDC was slightly higher than neoPDC due to more patients undergoing definitive surgery. However, for patients receiving surgery, the estimated cost was slightly lower for those receiving NPDC compared to neoPDC, primarily due to eligibility for minimally invasive and less costly surgeries. Estimated MRU costs were slightly higher for patients receiving NPDC due to pre-medications prescribed for the prevention of immune-mediated AE. Overall, patients receiving NPDC had lower estimated costs from AE, surgery, and other MRU compared to those receiving neoPDC.

Keywords

adverse events

surgery

medical resource use

resectable non-small cell lung cancer

neoadjuvant nivolumab plus platinum doublet chemotherapy

CheckMate-816 trial

costs per patient

adjuvant therapy

surgical complications

minimally invasive surgeries